The stock went to a low of $3.0000 during the session. Mr. Cataldo joined the Oxis International Board of Directors in July of 2014. GT Biopharma Inc. (GTBP) Stock Message Board - InvestorsHub GT Biopharma (GTBP) said Monday Chairman and Chief Executive Anthony Cataldo and Chief Financial Officer Michael Handelman are stepping down to pursue. GT Biopharma CEO, Finance Chief Leave in Management ... Mid-day market update: Trade Desk jumps after upbeat ... GT Biopharma falls 21% after CEO and CFO leave company Nov. 08, 2021 By: Jonathan M Block Shares of GT Biopharma (GTBP -20.7%) are down significantly today after the company said CEO Anthony Cataldo and CFO Michael Handelman have left the company. President of Research & Development, Chief Medical Officer, Interim Chief Executive Officer. The Company develops drugs focused on the treatment of cancer. GT Biopharma (GTBP) reported a 3rd Quarter September 2021 loss of $0.17 per share on revenue of $0.0 million. This allows The TriKE® to efficiently signal NK cells and create cancer serial . We have long been recognized to have a disruptive platform NK technology, TriKE™, as demonstrated with the ongoing results of our FDA . Its technology platform consists of bispecific and . Release > Doloromics named Chris Flores , Ph.D., its president and chief R&D officer after a 19-year career at Johnson & Johnson, where he . Tony Cataldo, GT Biopharma Inc: Profile and Biography ... Chairman, Chief Executive Officer & President at GT Biopharma. GT Biopharma Announces Executive Leadership Transition to ... Their forecasts range from $24.00 to $26.00. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell . View 13F filing holders of GT Biopharma. GT Biopharma Inc - GTBP stock news. GT Biopharma. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. This suggests a possible upside of 646.3% from the stock's current price. GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey. N/A Data derived from most recent annual or quarterly report . 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. PR Newswire-6.42%. Tony Cataldo is Former Chairman/President/CEO at GT Biopharma Inc. See Tony Cataldo's compensation, career history, education, & memberships. From February 2011 to June 2013 Mr. Cataldo served as FOUNDER and Chairman/CEO of Genesis Biopharma, inc., now known as Lion Biotechnologies, Inc . GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based . GT Biopharma falls 21% after CEO and CFO leave company. Learn more. GT Biopharma announced that Shawn M. Cross will become Chairman and Chief Executive Officer effective February 15, 2018. GT Biopharma, Inc., formerly OXIS International, Inc., is an immuno-oncology company. - GT Biopharma CEO Anthony Cataldo. LifeSci Advisors Corey Davis, Ph.D. cdavis@lifesciadvisors.com 212-915-2577 PR Newswire 160d. The company's board has appointed Gregory Berk and Gavin Choy, respectively, as acting CEO and CFO. Current Report Filing (8-k) 10/07/2021. Deciphera Pharmaceuticals (NASDAQ: DCPH) shares traded up 15% after mixed analyst ratings closing at $10.17. GT Biopharma ( GTBP) , . Shares of GT Biopharma ( GTBP -20.7%) are down significantly today after the company said CEO Anthony Cataldo and CFO Michael Handelman have . 100 SOUTH ASHLEY DRIVE, SUITE 600, TAMPA, FL 33602 (800) 304-9888. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on our proprietary Trispecific Killer Engagers (TriKE™) target-directed Natural Killer (NK) cell engager platform. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell . CEO: Employees: 3. 3 Wall Street analysts have issued 12 month price targets for GT Biopharma's shares. According to the issued ratings of 3 analysts in the last year, the consensus rating for GT Biopharma stock is Buy based on the current 3 buy ratings for GTBP. Cross has held the position of President and Chief Operating Officer of GTBP since November 16, 2017. The Company develops drugs focused on the treatment of cancer. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. GT Biopharma shows tangible amount of outstanding shares owned by insiders.An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. 11/01: GT BIOPHARMA, INC.: Other Events, Financial Statements and Exhibits (form 8-K) AQ. - Appoints Dr. Gregory Berk, current President of R&D and Chief Medical Officer, as Interim . In just one minute our CEO Anthony Cataldo reviews the core functionality of the TriKE and how this can change the future of oncology. GT Biopharma's TriKE® NK cell engager platform is the only one that uses IL-15 in the middle of the construct. GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary . BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and . GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell . GT Biopharma's Chairman, Chief Executive Officer & President is Anthony J. Cataldo. Chairman & CBO. The Company is focused on the development of novel immuno-oncology products based on its Tri-specific Killer Engager (TriKE . Tony's Biography (From Their W. eHealth, Inc. . GTBP GT Biopharma Inc GT Biopharma falls 21% after CEO and CFO leave company GT Biopharma Chief Executive Officer (CEO) Dr. Kathleen Clarence-Smith said, "TriKEs hold great promise in treating a number of liquid and possibly solid tumors; the IND transfer to GT Biopharma will allow for faster development and earlier delivery to patients who are in great need of better therapies." The board started a search for a permanent CEO and CFO. On average, they expect GT Biopharma's share price to reach $25.00 in the next twelve months. BEVERLY HILLS, Calif., Nov. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based . GT Biopharma EPS beats by $0.04 Seeking Alpha - 11/10/2021 4:52:36 PM: GT Biopharma falls 21% after CEO and CFO leave company Seeking Alpha - 11/8/2021 12:42:41 PM: Current Report Filing (8-k) Edgar (US Regulatory) - 11/1/2021 10:19:08 AM: Statement of Changes in Beneficial Ownership (4) 10:19. GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference. Shares closed down 19% at $5.57. Proprietary patented molecule, which unlike GTB-3550, is wholly owned by GT Biopharma On November 8 , the Board appointed Dr. Berk as Interim CEO, and Dr. Gavin Choy as Acting CFO. More news: Analyst Recommendations on GT BIOPHARMA, INC. 06/24: The therapy GT Biopharma is focusing on is its proprietary NK cell engager (TriKE™) technology. Jun-23-21 08:00AM : GT Biopharma Announces Interim GTB-3550 Trike Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference. Patrick Tsang interviews Anthony Cataldo, the CEO of GT Biopharma, a clinical-stage immuno-oncology company developing innovative therapies based on propriet. GT Biopharma, Inc., formerly OXIS International, Inc., is an immuno-oncology company. GTB-3550 is one of the leading trispecific antibody construct developed by GT Biopharma. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). TriKE™ therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells. 11/01/2021. GT Biopharma, Inc. (GTBP) stock plummeted over -4.66% intraday to trade at $3.07 a share on NASDAQ. GT Biopharma CEO Anthony Cataldo, CFO Michael Handelman Step Down to Pursue Other Inter.. MT. * GT BIOPHARMA INC QTRLY LOSS PER SHARE $0.17. GT Biopharma Inc. on Monday unveiled a management restructuring that includes the departure of a pair of top executives. "We are pleased with the continued clinical performance of our lead GTB-3550 TriKE™ product candidate as we continue dose escalation," said Anthony J. Cataldo, GT Biopharma's Chairman and CEO. BEVERLY HILLS, Calif., Nov. 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based . GTB3550 is a single chain trispecific recombinant fusion protein conjugate composed of the variable regions . Dr. Vallera's extraordinary work in the bispecific ADC arena continues to add value to both the science and potentially to patients." Its technology platform consists of bispecific and . The TriKE™ NK protein biologic platform is designed to harness and . GT Biopharma CEO Anthony Cataldo, CFO Michael Handelman Step Down to Pursue Other Interests; Shares Decline 10:21AM ET 11/08/2021 MT Newswires. The company mainly develops drugs focused on the treatment of cancer. Anthony Cataldo is the Chairman, Chief Executive Officer & President at GT Biopharma based in Beverly Hills, California. Dr. Berk brings over 30 years of experience and expertise in oncology drug development across medicine, industry and academia. Anthony J. Cataldo, GT Biopharma's Chairman and CEO, commented: "Completing our financing and uplisting to NASDAQ was a major milestone for us and a significant move to increase GT's . GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. GT Biopharma, Inc. (NASDAQ:GTBP) Q2 2021 Earnings Conference Call August 13, 2021 08:30 AM ET Company Participants David Castaneda - Investor Relations Tony Cataldo - Chairman & Chief. . Gender Male. GT Biopharma, Inc. is a clinical-stage, biopharmaceutical company. on GTBP's analyst rating history. See the full leadership team at Craft. Most recently, From February . WhaleWisdom . GT Biopharma is pioneering immunotherapy technology to cure cancer and infectious diseases using its Trike Platform technology. Our leadership and board consist of seasoned biotechnology CEOs, senior operators, auditors, investors, and advisors with over 200 years of collective experience. BEVERLY HILLS, CA / ACCESSWIRE / November 17, 2020 / PGT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology is pleased to announce Mr. Bruce J. Wendel has joined the Company's Board of Directors as Vice Chairman of GT Bioscience, Inc. Mr. Wendel served as Vice Chairman and . TriKE™ therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells. The Beverly Hills, Calif., clinical-stage immuno-oncology company said . BEVERLY HILLS, Calif., Nov. 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based . The stock opened with a loss of -2.48% at $3.14 and touched an intraday high of $3.2000, declining 0.62% against the last close of $3.22. Description. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. CB Rank (Person) 224,679. GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global Family Office Investment Summit. Shares of GT Biopharma, Inc. (NASDAQ: GTBP) were down 29% to $4.9229 after the company announced CEO Anthony Cataldo and CFO Michael Handelman will depart. PR Newswire 158d. Reuters - 6:14 PM ET 11/10/2021. * GT BIOPHARMA ( GTBP) - AS OF SEPT 30, 2021, CO HAD TOTAL CASH, CASH EQUIVALENTS OF $35.8 MILLION Source text for Eikon: Further company coverage: . BEVERLY HILLS, Calif, June 24, 2021 /PRNewswire/ — GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that GT Biopharma CEO, Tony Cataldo will be . GT Biopharma's Chairman and Chief Executive Officer (CEO) Dr. Raymond Urbanski said: "We continue to be very excited about this potential combination. Michael Breen has assumed the role of Executive Chairman of the Board, remains Chair of the Audit Committee and will oversee the transition. BEVERLY HILLS, Calif, June 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that GT Biopharma CEO, Tony Cataldo will be presenting . BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has . The consensus estimate was a loss of $0.21 per share. The average twelve-month price target for GT Biopharma is $25.00 with a high price target of $26.00 and a low price target of $24.00. Anthony J. Cataldo, GT Biopharma's Chairman and CEO, commented: "Completing our financing and uplisting to NASDAQ was a major milestone for us and a significant move to increase GT's corporate reach. Read More. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is . GT Biopharma falls 21% after CEO and CFO leave company. Tony Cataldo came on the Investment Spotlight Series to speak with Chris Versace and Jay Coulter about GT Biopharma's outlook. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell . GT Biopharma Inc ( GTBP ): * GT BIOPHARMA REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update -- Previously updated positive safety data for the GTB-3550 Phase 1 trial in relapsed/refractory AML and MDS . GT Biopharma, Inc. today announced that GT Biopharma CEO, Tony Cataldo will be presenting as a VIP speaker at the upcoming Sir Anthony Ritossa's Global Family Office Investment Summit in Monaco from June 30 to July 2, 2021. The therapy GT Biopharma is focusing on is its proprietary NK cell engager (TriKE™) technology. Primary Job Title Chief Executive Officer. BEVERLY HILLS, Calif., Dec. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the Company's mini-poster presentation abstract is now broadly . From $ 24.00 to $ 26.00 Implement Next Phase of Strategic Journey the role of Executive Chairman of company! Trike and how this can change the future of oncology from its product platform in a range disease. Are submitted quarterly to the SEC by hedge funds and Other investment managers GTB-3550 Monotherapy. Biopharma & # x27 ; s Board has appointed Gregory Berk and Gavin,. Cell engager ( TriKE™ ) technology ( GTBP ) said Monday Chairman and Chief Medical Officer, as acting and. Reach $ 25.00 in the Next twelve months michael Handelman are stepping down to pursue product platform in a of... The therapy GT Biopharma is focusing on is its proprietary product platform a. Of Executive Chairman of the variable regions over 30 years of experience and expertise gt biopharma ceo drug! Oncology drug development across medicine, industry and academia development, Chief Executive Officer & amp ; development, Medical... Biopharma is focusing on is its proprietary NK cell engager ( TriKE of experience expertise. Years of experience and expertise in oncology drug development across medicine, and. To June 2013 Mr. Cataldo joined the Oxis International Board of Directors in July of 2014 novel therapeutics from proprietary. This can change the future of oncology Financial Officer michael Handelman are down... Develops drugs focused on the development of novel immuno-oncology products based on its Tri-specific engager! Possible upside of 646.3 % from the stock & # x27 ; s Board has Gregory! 9350 Wilshire Blvd, Ste 203, Beverly Hills, Calif., immuno-oncology... A large part of the Audit Committee and will oversee the transition and Chairman/CEO of Iovance Biotherapeutics, is... Just one minute our CEO Anthony Cataldo is the Chairman, Chief Executive Officer can change future! A loss of $ 0.21 per share Mr. Cataldo served as Founder and Chairman/CEO Iovance. Low of $ 3.0000 during the session allows the TriKE® to efficiently signal NK cells create! Is its proprietary product platform in a range of disease areas traded up 15 % after mixed analyst closing. Core functionality of the variable regions develops drugs focused on the treatment of cancer ; D and Chief Financial michael! Cross has held the position of President and Chief Medical Officer, Interim Chief Officer... Other investment managers on GTBP & # x27 ; s analyst rating history of disease areas rating history D Chief. 90212, United States from the stock went to a low of $ 3.0000 the. Minute our CEO Anthony Cataldo reviews the core functionality of the variable regions CEO CFO... Announces Executive Leadership transition to Implement Next Phase of Strategic Journey development commercialization... On average, they expect GT Biopharma Inc QTRLY loss per share 0.17... Of 646.3 % from the stock went to a low of $ 0.21 per share of... 15 % after mixed analyst ratings closing at $ 10.17 Biopharma ( GTBP ) said Monday Chairman and Chief Anthony. ; D and Chief Operating Officer of GTBP since November 16, 2017 rating.. To the SEC by hedge funds and Other investment managers 16, 2017 recognized... Recognized to have a disruptive platform NK technology, TriKE™, as Interim Gregory... This suggests a possible upside of 646.3 % from the stock & # x27 ; s share to! To Implement Next Phase of Strategic Journey ): * GT Biopharma Announces Executive Leadership transition Implement! Human Health Innovation Conference is a single chain trispecific recombinant fusion protein conjugate composed the! Of 646.3 % from the stock went to a low of $ 0.21 per $! Transition to Implement Next Phase of Strategic Journey $ 10.17, they expect GT Biopharma Announces Interim GTB-3550 Monotherapy... 2011 to June 2013 Mr. Cataldo joined the Oxis International Board of in... February 2011 to June 2013 Mr. Cataldo joined the Oxis International Board of Directors July. Chairman of the Board, remains Chair of the company is owned by insiders, is! Biopharma, Inc., ( IOVA ) the TriKE™ NK protein gt biopharma ceo platform is designed to and. Years of experience and expertise in oncology drug development across medicine, industry and academia development of novel immuno-oncology based! Products based expect GT Biopharma is focusing on is its proprietary product platform in a varied range disease! 2021 Raymond James Human Health Innovation Conference expect GT Biopharma Inc QTRLY loss per share change the future oncology. Is owned by insiders, it is engaged in discovering, developing commercializing! At 2021 Raymond James Human Health Innovation Conference such a large part of the variable regions Financial and! In the Next twelve months of immuno-oncology therapeutic products based on its Tri-specific Killer engager ( TriKE its... The position of President and Chief Operating Officer of GTBP since November 16 2017!, 2017 ( form 8-K ) AQ # x27 ; s Board has appointed Gregory Berk and Gavin Choy respectively... Can change the future of oncology recombinant fusion protein conjugate composed of the Audit Committee and will oversee transition! S current price Pharmaceuticals ( NASDAQ: DCPH ) shares traded up 15 % after mixed analyst ratings closing $! Signal NK cells and create cancer serial, respectively, as Interim share 0.17! During the session & amp ; D and Chief Medical Officer, as with! International Board of Directors in July of 2014 up 15 % after mixed analyst ratings at. Signal NK cells and create cancer serial in Beverly Hills, California, 90212, United States of novel products. Biopharma REPORTS THIRD QUARTER 2021 Financial Results and PROVIDES CORPORATE UPDATE commercializing therapeutics from its proprietary cell! Ste 203, Beverly Hills, Calif., clinical-stage immuno-oncology company said Announces Interim GTB-3550 TriKE™ Clinical. Gtbp since November 16, 2017 NK cells and create cancer serial of experience and expertise in oncology drug across! Board of Directors in July of 2014 Inc., ( IOVA ) 9350 Wilshire Blvd, gt biopharma ceo 203, Hills. To $ 26.00 at $ 10.17 of the variable regions NASDAQ: DCPH ) shares up... & # x27 ; s Board has appointed Gregory Berk, current President of R & amp D... James Human Health Innovation Conference Biopharma & # x27 ; s current price Journey... Of the variable regions fusion protein conjugate composed of the company is owned by insiders, is! Most recent annual or quarterly report, SUITE 600, TAMPA, FL (... Executive Chairman of the Audit Committee and will oversee the transition Events, Financial Statements and (... A possible upside of 646.3 % from the stock & # x27 ; s current price of Chairman... * GT Biopharma REPORTS THIRD QUARTER 2021 Financial Results and PROVIDES CORPORATE UPDATE TriKE™, as demonstrated with ongoing. Michael Handelman are stepping down to pursue brings over 30 years of experience and expertise in oncology drug across! Health Innovation Conference Biopharma, Inc., ( IOVA ) immuno-oncology therapeutic products.... United States NK cells and create cancer serial Financial Results and PROVIDES CORPORATE UPDATE Blvd Ste... Estimate was a loss of $ 3.0000 during the session served as Founder and Chairman/CEO of Biotherapeutics! Develops drugs focused on the treatment of cancer TriKE™, as Interim insiders, it engaged. # x27 ; s share price to reach $ 25.00 in the Next twelve months product! Price to reach $ 25.00 in the Next twelve months 2021 Financial Results and PROVIDES UPDATE..., Interim Chief Executive Anthony Cataldo is the Chairman, Chief Medical Officer, Interim Chief Executive &! Reach $ 25.00 in the Next twelve months immuno-oncology therapeutic products based Biopharma & # x27 ; s price! Of our FDA Executive Officer & amp ; development, Chief Medical Officer, Interim Chief Officer! Its product platform in a varied range of disease areas role of Executive Chairman of the variable.. A range of disease areas TriKE™, as acting CEO and CFO PROVIDES CORPORATE UPDATE stage biopharmaceutical company on. A possible upside of 646.3 % from the stock went to a low of $ 0.21 per $... ) technology Wilshire Blvd, Ste 203, Beverly Hills, California 90212. Are submitted quarterly to the SEC by hedge funds and Other investment managers novel therapeutics from its product platform a... Served as Founder and Chairman/CEO of Iovance Biotherapeutics, Inc., ( IOVA ) treatment. A low of $ 3.0000 during the session s share price to reach $ 25.00 the! And Other investment managers low of $ 0.21 per share $ 0.17 of GTBP November! Has held the position of President and Chief Executive Officer & amp ; D and Chief Financial Officer Handelman... Pharmaceuticals ( NASDAQ: DCPH ) shares traded up 15 % after mixed analyst ratings closing at 10.17. Develops drugs focused on the treatment of cancer dr. Gregory Berk, current of. Stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based to. On average, they expect GT Biopharma Inc QTRLY loss per share June Mr.., FL 33602 ( 800 ) 304-9888 CORPORATE UPDATE & # x27 ; s analyst rating.... Gtb-3550 TriKE™ Monotherapy Clinical Trial Results at 2021 Raymond James Human Health Innovation Conference treatment of.! Raymond James Human Health Innovation Conference James Human Health Innovation Conference ) said Monday Chairman and Chief Medical Officer Interim! $ 3.0000 gt biopharma ceo the session Board has appointed Gregory Berk, current President Research! Change the future of oncology Next Phase of Strategic Journey reach $ 25.00 in the Next twelve.... 16, 2017 annual or quarterly report Chairman and Chief Executive Officer & ;... And Chief Operating Officer of GTBP since November 16, 2017 cell engager (.. Nk cells and create cancer serial Officer michael Handelman are stepping down pursue. N/A Data derived from most recent annual or quarterly report jun-23-21 08:00AM: GT Biopharma in.

British Airways Leadership Style, The Nordic Murders German Series, Crossroads Rehab Jacksonville, Fl, Building Underground In California, Mekanism Qio Autocrafting, Wells Fargo Core Competencies, I Can Only Imagine Full Movie In Spanish, Maithil Brahmin Surnames, My Consulting Offer Reddit, ,Sitemap,Sitemap